{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:45:30Z","timestamp":1789191930863,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00520-022-07400-z","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T14:03:48Z","timestamp":1666188228000},"page":"9803-9809","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Risk factors associated with palbociclib-induced neutropenia in patients with metastatic breast cancer"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8865-0064","authenticated-orcid":false,"given":"Lesli","family":"Lavery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristyn","family":"DiSogra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Lea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally J.","family":"Trufan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Symanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald C.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arielle","family":"Heeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,19]]},"reference":[{"issue":"20","key":"7400_CR1","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925\u20131936","journal-title":"N Engl J Med"},{"issue":"20","key":"7400_CR2","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J et al (2018) Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 379(20):1926\u20131936","journal-title":"N Engl J Med"},{"key":"7400_CR3","unstructured":"(2019) Ibrance (palbociclib) [prescribing information]. Pfizer Labs, New York"},{"issue":"3","key":"7400_CR4","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.stem.2015.01.017","volume":"16","author":"E Laurenti","year":"2015","unstructured":"Laurenti E, Frelin C, Xie S et al (2015) CDK6 level regulate quiescence exit in human hematopoietic stem cells. Cell Stem Cell 16(3):302\u2013313","journal-title":"Cell Stem Cell"},{"key":"7400_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13058-018-0958-2","volume":"20","author":"JK Kish","year":"2018","unstructured":"Kish JK, Ward MA, Garofalo D et al (2018) Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced\/metastatic breast cancer treated in community oncology practice in the USA one year post approval. Breast Cancer Res 20:37","journal-title":"Breast Cancer Res"},{"key":"7400_CR6","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0142","volume":"22","author":"LM Spring","year":"2017","unstructured":"Spring LM, Zangardi ML, Moy B et al (2017) Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4\/6 inhibitors in breast cancer: practical considerations and recommendations. Oncologist 22:1039\u20131048","journal-title":"Oncologist"},{"issue":"3","key":"7400_CR7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/14737140.2021.1852934","volume":"21","author":"CE Onesti","year":"2021","unstructured":"Onesti CE, Jerusalem G (2021) CDK4\/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. Expert Rev Anticancer Ther. 21(3):283\u2013298","journal-title":"Expert Rev Anticancer Ther."},{"issue":"5","key":"7400_CR8","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10637-014-0120-7","volume":"32","author":"LM Gelbert","year":"2014","unstructured":"Gelbert LM, Cai S, Lin X et al (2014) Preclinical characterization of the CDK4\/6 inhibitor LY2835219: in-vivo cell cycle-dependent\/independent anti-tumor activities alone\/in combination with gemcitabine. Invest New Drugs 32(5):825\u2013837","journal-title":"Invest New Drugs"},{"key":"7400_CR9","unstructured":"Chang JC, Gong S, Wang R et al (2019) Evaluation of race and body mass index on risk of palbociclib-induced neutropenia. Miami Breast Cancer Conference; March 7\u201310, Miami. Abstract 713"},{"key":"7400_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JGO.19.11000","volume":"5","author":"S-A Im","year":"2019","unstructured":"Im S-A, Mukai H, Park IH et al (2019) Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer: results from the phase III, randomized, PALOMA-2 study. J Glob Oncol 5:1\u20139","journal-title":"J Glob Oncol"},{"issue":"12","key":"7400_CR11","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1634\/theoncologist.2019-0019","volume":"24","author":"V Dieras","year":"2019","unstructured":"Dieras V, Harbeck N, Abraham Joy A et al (2019) Palbociclib with letrozole in postmenopausal women with ER+\/HER2- advanced breast cancer: hematologic safety analysis of the randomized PALOMA-2 trial. Oncologist 24(12):1514\u20131525","journal-title":"Oncologist"},{"issue":"7","key":"7400_CR12","doi-asserted-by":"publisher","first-page":"e1143","DOI":"10.1002\/onco.13811","volume":"26","author":"H Iwata","year":"2021","unstructured":"Iwata H, Umeyama Y, Liu Y et al (2021) Evaluation of the association of polymorphisms with palbociclib-induced neutropenia: pharmacogenomic analysis of PALOMA-2\/-3. Oncologist 26(7):e1143\u2013e1155","journal-title":"Oncologist"},{"key":"7400_CR13","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017. National Institutes of Health, National Cancer Institute, https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Accessed 28 August 2021"},{"key":"7400_CR14","unstructured":"Centers for Disease Control and Prevention. Defining adult overweight and obesity. https:\/\/www.cdc.gov\/obesity\/adult\/defining.html. Accessed 9 September 2021"},{"issue":"11","key":"7400_CR15","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1007\/s00198-009-1145-1","volume":"21","author":"KA Toulis","year":"2010","unstructured":"Toulis KA, Anastasilakis AD (2010) Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab. Osteoporos Int 21(11):1963\u20131964","journal-title":"Osteoporos Int"},{"issue":"2","key":"7400_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap) \u2013\u00a0a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 42(2):377\u201381","journal-title":"J Biomed Inform."},{"key":"7400_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN (2019) REDCap Consortium, The REDCap consortium: building an international community of software partners. J Biomed Inform. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208","journal-title":"J Biomed Inform"},{"issue":"1","key":"7400_CR18","doi-asserted-by":"publisher","first-page":"20055","DOI":"10.1038\/s41598-021-99504-5","volume":"11","author":"Y Kanbayashi","year":"2021","unstructured":"Kanbayashi Y, Sakaguchi K, Ishikawa T et al (2021) Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis. Sci Rep 11(1):20055","journal-title":"Sci Rep"},{"issue":"6","key":"7400_CR19","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1007\/s00520-020-05842-x","volume":"29","author":"Y Saito","year":"2021","unstructured":"Saito Y, Takekuma Y, Kobayashi M et al (2021) Detection of risk factors related to administration suspension and severe neutropenia in gemcitabine and nab-paclitaxel treatment. Support Care Cancer 29(6):3277\u20133285","journal-title":"Support Care Cancer"},{"issue":"8","key":"7400_CR20","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00520-010-0928-4","volume":"19","author":"S Ahn","year":"2011","unstructured":"Ahn S, Lee Y-S, Chun Y-H et al (2011) Predictive factors for poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia. Support Care Cancer 19(8):1151\u20131158","journal-title":"Support Care Cancer"},{"issue":"5","key":"7400_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.esmoop.2021.100231","volume":"6","author":"M Del Re","year":"2021","unstructured":"Del Re M, Omarini C, Diodati L et al (2021) Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open 6(5):1\u20136","journal-title":"ESMO Open"},{"issue":"1","key":"7400_CR22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","volume":"21","author":"R Coleman","year":"2020","unstructured":"Coleman R, Finkelstein DM, Barrios C et al (2020) Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 21(1):60\u201372","journal-title":"Lancet Oncol"},{"issue":"19","key":"7400_CR23","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1002\/cncr.33620","volume":"127","author":"F Lynce","year":"2021","unstructured":"Lynce F, Blackburn MJ, Zhuo R et al (2021) Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer. Cancer 127(19):3622\u20133630","journal-title":"Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07400-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-07400-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07400-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T13:22:00Z","timestamp":1669900920000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-07400-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,19]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7400"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-07400-z","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,19]]},"assertion":[{"value":"22 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a retrospective study. The Atrium Health Institutional Review Board approved the study and has confirmed that no ethical approval is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Lesli Lavery, Kristyn DiSogra, Julia Lea, Sally Trufan, James Symanowski, Ashley Roberts, and Sridhar Pal report no conflicts of interest. Don Moore reports advisory board\/consulting for Oncopeptides, Pfizer, Janssen, and AstraZeneca and Arielle Heeke reports consulting for Pfizer.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}